Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115517 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
A Phase 2 study of Pterygium, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT01115517 is a Phase 2 study of Pterygium that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 51 participants, below the 249-participant average among 3 other Pterygium trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01115517, a Phase 2 study of Pterygium, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence. A pterygium is a white fleshy growth on the surface of the eye, which can be removed surgically. However, after surgical removal, pterygia can recur. One way of minimizing recurrence is by applying a medication called mitomycin C to the surface of the eye during pterygium surgery. However, mitomycin is associated with certain side effects, such as thinning of the eye wall and poor wound healing. Bevacizumab has a different mechanism of action and there is some evidence that it may be useful in preventing pterygium recurrence. In this study, the safety and efficacy of adjunctive intraoperative use of bevacizumab and mitomycin C for preventing pterygium recurrence will be directly compared.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Mitomycin C
Study Locations (2)
Texas
- Lyndon B. Johnson General Hospital - Houston
- Robert Cizik Eye Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01115517
The ClinicalTrials.gov registry entry for NCT01115517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 249-participant average among 3 other Pterygium trials with a reported enrollment target (80% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pterygium appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01115517 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01115517 about?
NCT01115517 is a clinical study titled "Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery". This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence. A pterygium is a white fleshy growth on the surface of the eye, which can be removed surgically. However, after surgical remov...
What is the current status of trial NCT01115517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2010-10. Estimated completion is 2015-07.
What conditions does trial NCT01115517 study?
This clinical trial studies the following conditions: Pterygium.
What interventions are being tested in trial NCT01115517?
The interventions under investigation include: Bevacizumab (DRUG), Mitomycin C (DRUG).
Who is sponsoring clinical trial NCT01115517?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115517 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pterygium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.